Activity of different anti-staphylococcal therapies, alone or combined, in a rat model of methicillin-resistant Staphylococcus epidermidis osteitis without implant.
We developed a rat model of methicillin-resistant Staphylococcus epidermidis (MRSE) osteitis without implant to compare the efficacy of vancomycin, linezolid, daptomycin, ceftaroline, rifampin either alone or in association with rifampin. A clinical strain of MRSE was inoculated into the proximal tibia. Following a 1-week infection period, rats received either no treatment or 3, 7 or 14 days of human equivalent antibiotic regimen. Quantitative bone cultures were performed throughout the 14 days period. The mean ± SD quantity of staphylococci in the bone after 1-week infection period was 4.5 ± 1.0 Log10 CFU/g bone with this bacterial load remaining stable after 3 weeks of infection (4.9 ± 1,4 Log10 CFU/g bone).Whereas vancomycin monotherapy was the most slowly bactericidal, ceftaroline monotherapy was the most rapidly bactericidal. The addition of rifampin significantly increased the bacterial reduction for vancomycin, linezolid and daptomycin. All tibias were sterilized after 2 weeks of treatment except for animals receiving vancomycin or daptomycin alone (66,6% and 50% of sterilization respectively). These results show that ceftaroline and linezolid alone remain good options in the treatment of MRSE osteitis without implant. The combination with rifampin increases the antibiotic effect of vancomycin and daptomycin lines.